To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Amprion poses ‘significant execution risk’
Moody’s believes Amprion’s €3.3bn, 10-year capex programme ‘will not only burden the company’s financial performance, but also test its technical and managerial capabilities’. A consortium of institutional investors led by Commerz Real spent €1.3bn recently acquiring 74.9% of Amprion.
